Constellation Pharmaceuticals (CNST) Receives a Hold from Oppenheimer

By Ryan Adsit

In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to Constellation Pharmaceuticals (CNSTResearch Report), with a price target of $20.00. The company’s shares closed last Thursday at $17.99.

According to, Olson is ranked 0 out of 5 stars with an average return of -4.8% and a 39.6% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, ACADIA Pharmaceuticals, and Frequency Therapeutics.

Constellation Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $42.29.

See today’s analyst top recommended stocks >>

The company has a one-year high of $59.49 and a one-year low of $6.01. Currently, Constellation Pharmaceuticals has an average volume of 557.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.